Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.58 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.58 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | ESR1 | P03372 | 1/20 | 0.58 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.58 |
| ▸ | FYN | P06241 | 1/20 | 0.58 |
| ▸ | PGR | P06401 | 1/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.58 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.58 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL205211 | 1.00 | CYSLTR1 (0.58) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL8500076 | 0.95 | CYP2C8 (0.57) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL8500074 | 0.95 | CYP2C8 (0.57) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL8496432 | 0.89 | CYSLTR1 (0.49) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL8496429 | 0.89 | CYSLTR1 (0.49) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL13950635 | 0.87 | CYSLTR2 (0.50) | CYSLTR1CYSLTR2MEN1KMT2AABCB11 | |
| SCHEMBL29120427 | 0.86 | CYP2C8 (0.47) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL692870 | 0.84 | CYSLTR2 (0.52) | CYSLTR1CYSLTR2 | |
| SCHEMBL692871 | 0.84 | CYSLTR2 (0.52) | CYSLTR1CYSLTR2 | |
| SCHEMBL27531782 | 0.84 | CYSLTR1 (0.58) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8617853-B2 | Ketoreductase polypeptides for the production of (S,E)-methyl 2-(3-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-hydroxypropyl)benzoate | CODEXIS, INC. (US) | 2013-12-31 | — | — | US | claimed |
| US-20120184000-A1 | KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF (S,E)-METHYL 2-(3-(3-(2-(7-CHLOROQUINOLIN-2-YL)VINYL)PHENYL)-3-HYDROXYPROPYL)BENZOATE | CODEXIS, INC. (US) | 2012-07-19 | — | — | US | claimed |
| EP-2203557-B1 | KETOREDUCTASE POLYPEPTIDES AND USES THEREOF | CODEXIS INC (US) | 2012-02-29 | — | — | EP | claimed |
| US-20090155863-A1 | KETOREDUCTASE POLYPEPTIDES AND USES THEREOF | CODEXIS, INC. (US) | 2009-06-18 | — | — | US | claimed |
| EP-4321156-A1 | FILM-COATED TABLET WITH IMPROVED STABILITY CONTAINING MONTELUKAST OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND LEVOCETIRIZINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Han Wha Pharma Co., Ltd. (KR) | 2024-02-14 | — | — | EP | disclosed |
| WO-2023068839-A1 | FILM-COATED TABLET WITH IMPROVED STABILITY CONTAINING MONTELUKAST OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND LEVOCETIRIZINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 한화제약주식회사 | 2023-04-27 | — | — | WO | disclosed |
| CN-111110679-A | Pharmaceutical composition containing montelukast sodium | 长春海悦药业股份有限公司 | 2020-05-08 | — | — | CN | disclosed |
| WO-2014081616-A1 | PREPARATION OF PRECURSORS FOR LEUKOTRIENE ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2014-05-30 | — | — | WO | disclosed |
| US-8617853-B2 | Ketoreductase polypeptides for the production of (S,E)-methyl 2-(3-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-hydroxypropyl)benzoate | CODEXIS, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| US-8569508-B2 | Synthetic method for montelukast sodium intermediate | SHANDONG NEW TIME PHARMACEUTICAL CO., LTD. (CN) | 2013-10-29 | — | — | US | disclosed |
| US-8569508-B2 | Synthetic method for montelukast sodium intermediate | SHANDONG NEW TIME PHARMACEUTICAL CO., LTD. (CN) | 2013-10-29 | — | — | US | disclosed |
| US-20120184000-A1 | KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF (S,E)-METHYL 2-(3-(3-(2-(7-CHLOROQUINOLIN-2-YL)VINYL)PHENYL)-3-HYDROXYPROPYL)BENZOATE | CODEXIS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-8088610-B2 | Ketoreductases for the production of (S,E)-methyl 2-(3-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-hroxypropyl)benzoate | CODEXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| WO-2011026398-A1 | SYNTHETIC METHOD OF MONTELUKAST SODIUM INTERMEDIATE | 山东新时代药业有限公司 (CN) | 2011-03-10 | — | — | WO | disclosed |
| WO-2010148209-A2 | PREPARATION OF MONTELUKAST | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010148209-A2 | PREPARATION OF MONTELUKAST | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-12-23 | — | — | WO | disclosed |
| US-20090155863-A1 | KETOREDUCTASE POLYPEPTIDES AND USES THEREOF | CODEXIS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155863-A1 | KETOREDUCTASE POLYPEPTIDES AND USES THEREOF | CODEXIS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155863-A1 | KETOREDUCTASE POLYPEPTIDES AND USES THEREOF | CODEXIS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2009042984-A1 | KETOREDUCTASE POLYPEPTIDES AND USES THEREOF | CODEXIS, INC. (US) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155863-A1 | KETOREDUCTASE POLYPEPTIDES AND USES THEREOF | TKT, DCXR, AKR1B1 | CYSLTR1 3689/4885CYP2C8 787/4885CYSLTR2 3723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.